Category: Pfizer
-
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies WASHINGTON — President Trump often brags that the “most-favored nation” deals he struck with drugmakers have set the country on a new path to no longer paying more than its fair share for prescription drug costs. But many details of the…
-
STAT+: On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A
STAT+: On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox. It’s Day 3 of JPM and all of us — Matt, Elaine, Adam, and Allison — are…
-
STAT+: Pfizer and Tris agree to $41.5 million settlement with Texas over ADHD drug for children
STAT+: Pfizer and Tris agree to $41.5 million settlement with Texas over ADHD drug for children Pfizer and Tris Pharma have agreed to pay $41.5 million to settle allegations by Texas Attorney General Ken Paxton that they provided an ADHD medicine to children on Medicaid while knowing about “flawed” manufacturing practices. The companies were accused…
-
Merck’s heart disease win and the FDA’s new drug regulator
Merck’s heart disease win and the FDA’s new drug regulator What does Rick Pazdur’s new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1 drug prices? Dean Li, the head of R&D at Merck, joins us to discuss…
-
STAT+: The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?
STAT+: The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets? At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera and its investigational obesity treatments. But in doing so, the company has also taken on significant risks. Will…
-
Melodrama at the FDA and the Pfizer-Novo bidding war
Melodrama at the FDA and the Pfizer-Novo bidding war On this week’s episode of “The Readout LOUD”: “Mean Girls” melodrama at the top of the FDA and the latest on the Pfizer-Novo Nordisk bidding war for Metsera. On a jam-packed show, your co-hosts, minus the vacationing Allison DeAngelis, chat with STAT’s D.C. correspondent Lizzy Lawrence…
-
STAT+: FTC raises concern about Novo Nordisk attempt to acquire obesity startup Metsera
STAT+: FTC raises concern about Novo Nordisk attempt to acquire obesity startup Metsera The Federal Trade Commission has raised concerns about Novo Nordisk’s attempt to outbid Pfizer to acquire obesity startup Metsera, the latest complication in a dramatic bidding war between two pharma giants. Companies normally have to seek FTC review for acquisitions under a…
-
A pharma C-suite shakeup and Trump’s deal with Pfizer
A pharma C-suite shakeup and Trump’s deal with Pfizer How will we look back on Emma Walmsley’s tenure as GSK’s CEO? Why did one of the FDA’s top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff? We discuss all that and more…
-
STAT+: The government is shut down. Now what?
STAT+: The government is shut down. Now what? You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Are you in a betting pool for how long the government shutdown will last? Send your…
-
STAT+: Trump, Pfizer, and the art of a drug pricing deal
STAT+: Trump, Pfizer, and the art of a drug pricing deal Amid all the hand-shaking and back-patting, it was perhaps the word “friendship” that stood out the most when the CEO of Pfizer joined President Trump to address a drug pricing deal in the Oval Office. “But most of all, Mr. President, I want to…
-
Trump strikes deal with Pfizer aimed at lowering prescription drug prices
Trump strikes deal with Pfizer aimed at lowering prescription drug prices WASHINGTON — President Trump announced on Tuesday that Pfizer has agreed to offer lower prices on its drugs to the Medicaid program and directly to patients, the first in what he said would be a series of deals intended to secure cheaper prescription medicines…
-
How do we know mRNA vaccines are safe and effective? An explainer
How do we know mRNA vaccines are safe and effective? An explainer Messenger RNA vaccines fueled the response to the worst pandemic the world has faced in a century and led to a Nobel Prize. This week, they’re set to face intense scrutiny from critics doubtful of the safety and efficacy of these shots. On…
-
RSV sent fewer babies to the hospital last winter, after new treatment and vaccine arrived
RSV sent fewer babies to the hospital last winter, after new treatment and vaccine arrived A new report from the Centers for Disease Control and Prevention shows there was a substantial drop in hospitalizations for respiratory syncytial virus this winter among very young children, who are at the highest risk of becoming severely ill if they contract…